In the EU, rare diseases that are also life-threatening or chronically debilitating with a low prevalence and a high level of complexity are defined as orphan diseases.
EuropaBio is a founding member of the EPAA – the European Platform for Alternative Approaches to
The purpose of HTA is to provide high-quality information to decision makers about the clinical e
Biological medicines are far more complex and usually much bigger than chemical medicines, which
There is no common European consensus on how to reward healthcare innovation.
Manufacturing biological medicines is generally more complex than the production of traditional (